Literature DB >> 27364372

Is arthrocentesis plus platelet-rich plasma superior to arthrocentesis plus hyaluronic acid for the treatment of temporomandibular joint osteoarthritis: a randomized clinical trial.

S Cömert Kiliç1, M Güngörmüş2.   

Abstract

A randomized clinical trial was implemented in adult patients with temporomandibular joint osteoarthritis (TMJ OA). The sample comprised 49 osteoarthritic joints in 31 consecutive patients. Patients were divided randomly into two groups according to the treatment technique applied: the platelet-rich plasma (PRP) group patients underwent initial arthrocentesis plus PRP injection and then four consecutive PRP injections; the hyaluronic acid (HA) group patients underwent one session of arthrocentesis plus HA injection. The predictor variable was the treatment technique. The outcome variables included visual analogue scale (VAS) evaluations and maximum inter-incisal opening (MIO) measurements. Outcome variables were recorded preoperatively and at 12 months postoperative. Descriptive and bivariate statistics were computed and significance was set at P<0.05. The PRP group included 32 joints in 18 subjects, and the HA group included 17 joints in 13 subjects. No statistically significant difference was observed between the groups for any of the changes in VAS parameters or MIO measurements. Both treatment techniques resulted in significant clinical improvements in all VAS parameters and painless MIO. These findings suggest that arthrocentesis plus PRP injections is not superior to arthrocentesis plus a single HA injection; thus PRP injection should not be considered as the first line treatment. Arthrocentesis plus HA injection would appear to be more acceptable for patients.
Copyright © 2016 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  TMJ osteoarthritis; arthrocentesis; hyaluronic acid; intra-articular injection; platelet-rich plasma

Mesh:

Substances:

Year:  2016        PMID: 27364372     DOI: 10.1016/j.ijom.2016.06.009

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  6 in total

Review 1.  Treatment of Mandibular Hypomobility by Injections into the Temporomandibular Joints: A Systematic Review of the Substances Used.

Authors:  Maciej Chęciński; Kamila Chęcińska; Zuzanna Nowak; Maciej Sikora; Dariusz Chlubek
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

2.  The influence of sample size and gender composition on the meta-analysis conclusion of platelet-rich plasma treatment for osteoarthritis.

Authors:  Kun Zhao; Yan-Shan Liu; Liu-Yan Nie; Lin-Na Qian; Nan-Fang Nie; Sebastian Leptihn; Varitsara Bunpetch; Jia-Qi Xu; Xiao-Hui Zou; Hongwei Ouyang
Journal:  J Orthop Translat       Date:  2019-11-15       Impact factor: 5.191

3.  Treatment of temporomandibular joint disc displacement using arthrocentesis combined with injectable platelet rich fibrin versus arthrocentesis alone.

Authors:  Nahed Ibrahim Ghoneim; Noha Ahmed Mansour; Sarah Ahmed Elmaghraby; Sally Elsayed Abdelsameaa
Journal:  J Dent Sci       Date:  2021-08-21       Impact factor: 2.080

4.  Long-Term Outcome of Horses Undergoing Unilateral Mandibular Condylectomy and Meniscectomy for Temporomandibular Joint Disease.

Authors:  Sarah A White; Nathan C Canada; James L Carmalt; James Schumacher; Fernando N Amitrano; Kyla Ortved; Travis J Henry; Sabrina H Brounts; Carolyn E Arnold
Journal:  Front Vet Sci       Date:  2022-05-02

5.  Repeated Intra-Articular Administration of Platelet-Rich Plasma (PRP) in Temporomandibular Disorders: A Clinical Case Series.

Authors:  Maciej Sikora; Marcin Sielski; Maciej Chęciński; Zuzanna Nowak; Barbara Czerwińska-Niezabitowska; Dariusz Chlubek
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

Review 6.  Interdisciplinary Approach to the Temporomandibular Joint Osteoarthritis-Review of the Literature.

Authors:  Marcin Derwich; Maria Mitus-Kenig; Elzbieta Pawlowska
Journal:  Medicina (Kaunas)       Date:  2020-05-09       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.